X0306 4 2022-01-18 0 0001396814 Pacira BioSciences, Inc. PCRX 0001296965 Williams Kristen Marie C/O PACIRA BIOSCIENCES, INC. 5401 WEST KENNEDY BOULEVARD, SUITE 890 TAMPA FL 33609 0 1 0 0 Chief Administrative Officer Common Stock 2022-01-18 4 M 0 1375 44.20 A 23643 D Common Stock 2022-01-18 4 M 0 2600 38.35 A 26243 D Common Stock 2022-01-18 4 M 0 6338 43.54 A 32581 D Common Stock 2022-01-18 4 M 0 13127 47.65 A 45708 D Common Stock 2022-01-18 4 S 0 23040 65.24 D 22668 D Common Stock 2022-01-18 4 S 0 400 66.14 D 22268 D Common Stock 2022-01-19 4 M 0 2199 38.35 A 24467 D Common Stock 2022-01-19 4 S 0 2199 65.51 D 22268 D Stock Option (Right to Buy) 44.20 2022-01-18 4 M 0 1375 0.00 D 2027-06-14 Common Stock 1375 0 D Stock Option (Right to Buy) 38.35 2022-01-18 4 M 0 2600 0.00 D 2028-06-13 Common Stock 2600 12165 D Stock Option (Right to Buy) 43.54 2022-01-18 4 M 0 6338 0.00 D 2029-06-05 Common Stock 6338 12672 D Stock Option (Right to Buy) 47.65 2022-01-18 4 M 0 13127 0.00 D 2030-06-09 Common Stock 13127 21873 D Stock Option (Right to Buy) 38.35 2022-01-19 4 M 0 2199 0.00 D 2028-06-13 Common Stock 2199 9966 D The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.02 to $65.95, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.07 to $66.27, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.055 to $65.880, inclusive. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. /s/ Kristen Williams 2022-01-20